Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.30 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL924045 | 0.88 | TLR8 (0.36) | ALDH1A1HSD17B10KMT2ATLR8 | |
| Bromide SCHEMBL923388 | 0.87 | TLR8 (0.35) | ALDH1A1HSD17B10KMT2ATLR8 | |
| SCHEMBL924681 | 0.86 | ALDH1A1 (0.45) | ALDH1A1HSD17B10KMT2ATLR8 | |
| SCHEMBL923794 | 0.80 | C1S (0.35) | ALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL12907306 | 0.74 | ALDH1A1 (0.33) | ALDH1A1HSD17B10 | |
| SCHEMBL924821 | 0.71 | ALDH1A1 (0.47) | ALDH1A1HSD17B10KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL923418 | 0.70 | MAPT (0.37) | ALDH1A1KMT2AMAPTTLR8SMN1; SMN2 | |
| SCHEMBL15888096 | 0.68 | ALDH1A1 (0.41) | ALDH1A1KMT2AMAPTTLR8SMN1; SMN2 | |
| SCHEMBL926457 | 0.66 | KMT2A (0.36) | ALDH1A1KMT2AMAPTTLR8SMN1; SMN2 | |
| SCHEMBL11250299 | 0.66 | KMT2A (0.36) | ALDH1A1KMT2AMAPTTLR8SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102632-B2 | Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2015-08-11 | — | — | US | disclosed |
| US-9102632-B2 | Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2015-08-11 | — | — | US | disclosed |
| US-9102632-B2 | Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2015-08-11 | — | — | US | disclosed |
| EP-2250156-B1 | PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2015-05-06 | — | — | EP | disclosed |
| EP-2250156-B1 | PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2015-05-06 | — | — | EP | disclosed |
| US-20140100235-A1 | PYRAZINONE DERIVATIVES AS INSULIN SECRETON STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2014-04-10 | — | — | US | disclosed |
| US-8637522-B2 | Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| US-8637522-B2 | Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| US-8637522-B2 | Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| US-20110015210-A1 | Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PAATENT GESELLSCHAFT (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20110015210-A1 | Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PAATENT GESELLSCHAFT (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20110015210-A1 | Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PAATENT GESELLSCHAFT (DE) | 2011-01-20 | — | — | US | disclosed |
| EP-2250156-A1 | PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | Merck Patent GmbH (DE) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009109259-A1 | PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109259-A1 | PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140100235-A1 | PYRAZINONE DERIVATIVES AS INSULIN SECRETON STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | GLP1R, GPR119, IAPP | ALDH1A1 3746/4885HSD17B10 1831/4885KMT2A 4823/4885 |
| US-20110015210-A1 | Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | GLP1R, IAPP, INSR | ALDH1A1 2942/4885HSD17B10 1292/4885KMT2A 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.